Results for
""Benzoxazines""[mesh_terms]

Efavirenz as a psychotropic drug.

D Velissaris, A Tsigkou, I Economou, F Pouliasi, A Karela, M Lagadinou, N Zareifopoulos

European review for medical and pharmacological sciences 2021;24(20):10729-10735

New insights into the transcriptional regulation of benzoxazinoid biosynthesis in wheat.

Elia Stahl

Journal of experimental botany 2022;73(16):5358-5360

An inverse association between plasma benzoxazinoid metabolites and PSA after rye intake in men with prostate cancer revealed with a new method.

Elise Nordin, Stine K Steffensen, Bente B Laursen, Sven-Olof Andersson, Jan-Erik Johansson, Per Åman, Göran Hallmans, Michael Borre, Dan Stærk, Kati Hanhineva, Inge S Fomsgaard, Rikard Landberg

Scientific reports 2022;12(1):5260

Implications of efavirenz for neuropsychiatry: a review.

G I T Cavalcante, V L M Capistrano, F S D Cavalcante, S M M Vasconcelos, D S Macêdo, F C F Sousa, D J Woods, M M F Fonteles

The International journal of neuroscience 2011;120(12):739-45

Benzoxazinoids in rye allelopathy - from discovery to application in sustainable weed control and organic farming.

Margot Schulz, Adriano Marocco, Vincenzo Tabaglio, Francisco A Macias, Jose M G Molinillo

Journal of chemical ecology 2013;39(2):154-74

Integrated study of antiretroviral drug adsorption onto calcined layered double hydroxide clay: experimental and computational analysis.

Shepherd Masimba Tichapondwa, Gbolahan Joseph Adekoya, Lehlogonolo Shane Tabana

Environmental science and pollution research international 2024;31(22):32282-32300

Recent data on the role of antiretroviral therapy in weight gain and obesity in persons living with HIV.

Jacqueline Capeau, Claire Lagathu, Véronique Béréziat

Current opinion in HIV and AIDS 2024;19(1):14-20

Early or deferred initiation of efavirenz during rifampicin-based TB therapy has no significant effect on CYP3A induction in TB-HIV infected patients.

Jürgen Burhenne, Getnet Yimer, Eyasu Makonnen, Wondwossen Amogne, Abiy Habtewold, Ulf Diczfalusy, Eleni Aklillu, Alimuddin Zumla

British journal of pharmacology 2021;178(16):3294-3308

Gut microbiota alterations after switching from a protease inhibitor or efavirenz to raltegravir in a randomized, controlled study.

Anna M Hanttu, Jussi P Sutinen, Kirsi H Pietiläinen, Perttu Arkkila, Anna K Hartikainen, Reetta Satokari, Satu Pekkala

AIDS (London, England) 2022;37(2):323-332

Structure and biosynthesis of benzoxazinoids: Plant defence metabolites with potential as antimicrobial scaffolds.

Jean-Paul Vincken, Harry Gruppen, Wouter J C de Bruijn

Phytochemistry 2018;155():233-243

Structure-activity relationship studies on clinically relevant HIV-1 NNRTIs.

R K Rawal, V Murugesan, S B Katti

Current medicinal chemistry 2013;19(31):5364-80

Dietary exposure to benzoxazinoids enhances bacteria-induced monokine responses by peripheral blood mononuclear cells.

Dres Damgaard, Bettina Margrethe Jensen, Yaseelan Palarasah, Michael Friberg Bruun Nielsen, Khem Bahadur Adhikari, Heidi Julius Schnoor, Nanna Juel-Berg, Inge S Fomsgaard, Claus Henrik Nielsen, Lars K Poulsen

Molecular nutrition & food research 2016;59(11):2190-8

Immunologic Change over 72 Weeks Following Raltegravir- Versus Efavirenz-Based Therapy in HIV/HCV-Coinfected Individuals in Vietnam.

Glen M Chew, Thao Vu Phuong, Thuy Le, Cecilia M Shikuma, Van Vinh Chau Nguyen, Lishomwa C Ndhlovu, Robert Paul, Louie Mar Gangcuangco, Thomas Premeaux, Nath Limpruttidham, Hayk Ghukasyan, Dominic Chow, Chathura Siriwardhana, Trieu Ly Vo

AIDS research and human retroviruses 2022;38(6):441-450

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial.

Otto Sussmann, Hedy Teppler, Elizabeth Martin, Carey Hwang, George J Hanna, Sushma Kumar, Gina Lin, Paul E Sax, Jean-Michel Molina, Kathleen E Squires, Chloe Orkin

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2021;73(1):33-42